Congress funds free smoking cessation for 70 million Medicaid beneficiaries

What it does

This bill requires Medicaid and CHIP (Children's Health Insurance Program) to cover tobacco cessation services—including counseling, prescription drugs, and FDA-approved over-the-counter smoking-cessation medications—at no cost to beneficiaries. The federal government will pay 90% of state costs for these services and related outreach campaigns for five years, then revert to standard matching rates. States must also monitor usage and run awareness campaigns, and cannot require prior authorization for cessation drugs.

Why we flagged it

The bill's core mechanism is straightforward: it mandates Medicaid/CHIP coverage of tobacco cessation services and funds state outreach. This is a direct public-health intervention, not a tax provision, regulatory carve-out, or commemorative measure.

What the text implies

• Tobacco companies face potential long-term demand reduction if cessation rates rise significantly among Medicaid/CHIP populations, which represent ~40% of U.S. smokers. This may accelerate industry shift toward alternative nicotine products.
• States will incur administrative costs for outreach and monitoring beyond the 90% federal match, creating ongoing state-budget pressure after the 5-year enhanced match period ends.
• The bill's reliance on 2008 clinical guidelines and FDA approval may lag emerging cessation science; amendment process could become a regulatory battleground if new therapies emerge.
• Exclusion of prior-authorization requirements for cessation drugs may increase utilization and pharmaceutical costs, though public-health ROI likely justifies the expense.

Who it affects

Ordinary people gain access to free, comprehensive smoking-cessation support through public insurance, removing financial barriers to quitting. Smokers in low-income households—who have higher smoking rates and fewer resources—benefit most. The public health return (reduced disease, mortality, healthcare costs) is substantial and well-documented.

Who stands to gain

• pharmaceutical companies (cessation drug manufacturers)
• healthcare providers (counseling services)
• state Medicaid programs (federal cost-sharing reduces state burden)

Named in the bill

Medicaid, CHIP, FDA, U.S. Preventive Services Task Force, Public Health Service, Social Security Act, Philip Morris (PM), Altria (MO), British American Tobacco (BTI), tobacco cessation drug manufacturers

Where it stands

1 cosponsor: 1 Democrats.

• Jun 12, 2025 — Introduced · Congress.gov: “Introduced in Senate”
• Jun 12, 2025 — Referred to Senate Committee on Finance · Congress.gov: “Read twice and referred to the Committee on Finance”

Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.

Money around this bill

1 lobbying clients named this bill on 1 disclosure filings across 1 quarter, Jun 2026 to Jun 2026. Those filings disclosed $1,240,000 in lobbying spend. A filing names 35 bills on average, so that figure is what each filing reported, not a share belonging to this bill.

More lobbying clients named this bill than 0% of bills with at least one filing.

Lisa Blunt Rochester, the sponsor, reported $317,500 in PAC receipts in the 2026 cycle.

• American Cancer Society Cancer Action Network Inc — $1,240,000 on 1 filing

Lobbying Disclosure Act filings through Jul 20, 2026. A filing shows who paid to lobby on a bill it names, not what changed.